3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neurofibrosarcoma
1
Melanoma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
pazopanib
2
thymoglobulin
1
sapanisertib
1
pexidartinib
1
pembrolizumab
1
fludarabine phosphate
1
Trabectedin
1
Thiotepa
1
Tacrolimus
1
Stem Cell Transplantation
1
Sirolimus
1
Radiotherapy, Intensity-Modulated
1
Polymerase Chain Reaction
1
Neoadjuvant Therapy
1
Mycophenolic Acid
1
Melphalan
1
Imatinib Mesylate
1
Gene Expression Profiling
1
Etoposide
1
Doxorubicin
1
Docetaxel
1
Cyclosporins
1
Cyclosporine
1
Blotting, Western
1
Antilymphocyte Serum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neurofibrosarcoma
×
pexidartinib
×
Clear all
NCT02584647
2025-03-21
PLX3397
Columbia University
Phase 1/2
Terminated
39 enrolled
13 charts